Streetbeat News

Products Services

BNTX

BioNTech's stock price increased following the announcement that the company will present clinical trial data for its oncology pipeline at the American Association for Cancer Research Annual Meeting 2024.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 2:31 pm

MNKD

MannKind Corporation (NASDAQ:MNKD) shares are in focus due to initial meal challenge data from INHALE-3, a Phase 4 clinical trial for inhaled insulin, showing promising results. The company also reported Q4 earnings of 2 cents per share with sales of $58.47 million, surpassing analyst estimates. CNBC's Jim Cramer discussed the stock, noting its potential for an earnings breakout. Analysts have a 12-month price target range of $6.50 to $7.50, with an average of $7.00. MannKind shares are currently down 8.35% at $4.82.

Portfolio Pulse from Erica Kollmann

March 11, 2024 | 2:28 pm

ABNB

Airbnb announced a global ban on indoor security cameras in its listings, effective April 30. Previously, cameras were permitted if disclosed in the listing. The policy change, influenced by feedback from guests, hosts, and privacy experts, aims to address privacy concerns. Outdoor cameras and doorbell cameras are still allowed if disclosed. Violations could lead to listing or account removal. The decision reflects the ongoing debate between hosts who view cameras as essential for property protection and guests concerned about privacy.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 2:17 pm

BITF

Bitfarms Ltd. (BITF) has announced the purchase of additional miners to reach a mining capacity of 21 EH/s in 2024. The company fully exercised a purchase option for 28,000 Bitmain T21 miners and bought an additional 19,280 Bitmain T21 miners, 3,888 Bitmain S21 miners, and 740 Bitmain S21 Hydro miners. These acquisitions are part of Bitfarms' expansion plan, aiming to operate one of the newest and most powerful mining fleets in anticipation of a bull market. The company plans to liquidate older miners to offset the cost of new ones and aims to improve hashrate, energy efficiency, and operating costs per terahash.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 2:11 pm

DUO

Fangdd Network Group Ltd (NASDAQ:DUO) stock surged 90% to $1.15 after announcing its strategic plan to enter the real estate stock asset services sector by 2024. The company aims to leverage its real estate transaction service experience to become a leading platform in this new sector, which is expected to provide new business opportunities and contribute to its long-term growth.

Portfolio Pulse from Henry Khederian

March 11, 2024 | 2:08 pm

ORCL

Oracle Corp (NYSE:ORCL) is in focus as it prepares to report its fiscal third-quarter financial results after market close. Expected earnings are $1.38 per share with revenue of $13.306 billion. Despite beating EPS estimates in recent quarters, Oracle has missed revenue estimates twice. Demand for its Cloud Infrastructure and Generative AI services is reportedly growing rapidly. Analysts have recently lowered price targets on Oracle. The stock was up 0.37% at $112.86.

Portfolio Pulse from Adam Eckert

March 11, 2024 | 2:04 pm

RKLB

A Reddit post titled 'Rocket Lab Bull Case' has ignited a debate among Redditors about Rocket Lab USA's (NASDAQ:RKLB) potential in the space industry compared to SpaceX. The post highlights Rocket Lab's valuation at $2 billion, its 44 successful launches, and its unique launch pad in New Zealand as key advantages. Despite skepticism regarding its financials and operational challenges, some Redditors see potential for growth, especially with the upcoming Neutron project. The discussion reflects diverse opinions on Rocket Lab's future in the rapidly growing space exploration market.

Portfolio Pulse from Surbhi Jain

March 11, 2024 | 1:57 pm

ABBV

MLTX

MoonLake Immunotherapeutics (NASDAQ:MLTX) reported significant improvements in psoriatic arthritis outcomes from the ARGO trial of Nanobody sonelokimab, surpassing results of AbbVie Inc's (NYSE:ABBV) Humira. MLTX plans to start Phase 3 trials in 2024, with shares up 3%.

Portfolio Pulse from Vandana Singh

March 11, 2024 | 1:56 pm

MESO

The U.S. FDA has indicated support for an accelerated approval pathway for Mesoblast Limited's rexlemestrocel-L, a treatment for end-stage ischemic heart failure patients with a left ventricular assist device (LVAD). This follows positive results from a pivotal study showing significant benefits, including reduced mortality and improved ability to wean off LVAD support. Mesoblast plans to request a pre-Biologics License Application meeting with the FDA to discuss further steps towards approval.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 1:48 pm

CERO

DUO

ELTK

JFBR

PIK

TCBP

U.S. stocks traded lower with the Dow Jones, NASDAQ, and S&P 500 all experiencing declines. Materials shares saw a rise, while information technology shares dropped. Eltek Ltd. reported disappointing earnings, while Kidpik Corp., Fangdd Network Group Ltd., and TC Biopharm (Holdings) Plc saw significant stock price increases. Conversely, Eltek Ltd., Jeffs' Brands Ltd, and CERo Therapeutics Holdings, Inc. experienced notable declines. Oil and gold traded lower, while silver and copper saw gains. European and Asian markets showed mixed results, with specific economic data highlighted for Spain, China, and Japan.

Portfolio Pulse from Avi Kapoor

March 11, 2024 | 1:48 pm